Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDR Brachytherapy and Nivolumab in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07152678Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Taiwan University Hospital. Primary endpoint: Cumulative incidence of locoregional failure at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07152678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152678.